Overview
This study aims to analyses time to disease relapse of RA patients if TNF- inhibitors are being tapered, the predictive factors that are associated with successful taper of TNFinhibitors. Also, investigate the effects associated with dose tapering of TNF- inhibitors.
Eligibility
Inclusion criteria:
Diagnosed of RA based on the 1987 American College of Rheumatology (ACR) criteria and/or 2010 ACR/EULAR classification criteria of RA depending on the time of diagnosis Age 20 years old TNF- inhibitors was prescribed for RA patients refractory to csDMARDs (defined as csDMARD therapy for over 6 months) during 2003/5/2 - 2017/4/30 Dose reduction or discontinuation use of TNF- inhibitors (2011/1/1-2019/4/30)
Exclusion criteria:
TNF- inhibitors were discontinued or tapered due to adverse events such as infection, liver transaminase elevation, malignancy and neutropenia.